Autologous hematopoietic stem cell transplant relies on successful recruitment of hematopoietic stem cells from the bone marrow to the peripheral blood in a process termed mobilization. This is most commonly achieved in patients with lymphoma by monotherapy with granulocyte colony‐stimulating factor (G‐CSF) or a combination of disease‐specific chemotherapy and G‐CSF prior to apheresis for stem cell collection. Failure to mobilize is an important issue resulting in poor patient outcomes and increased utilization of resources. Addition of the chemokine receptor antagonist plerixafor helps remobilization and proactively prevents failure in poor mobilizers. This chapter discusses methods for mobilization and addresses the issues involved in determining who will mobilize poorly and how to treat these patients.